Brief: Shanghai Junshi Biosciences Says Technology Development Contract With Shanghai Allink Biotherapeutics
30/01/2024 11:19
Jan 30 (Reuters) - Shanghai Junshi Biosciences Co Ltd
688180.SS :
* TECHNOLOGY DEVELOPMENT CONTRACT FOR CELL LINE DEVELOPMENT
AND
PRODUCTION OF DRUG SUBSTANCES AND PREPARATIONS
* TOTAL CONTRACT PRICE IS RMB40 MILLION
* CO ENTERED INTO TECHNOLOGY DEVELOPMENT CONTRACT WITH
SHANGHAI
ALLINK BIOTHERAPEUTICS
Source text for Eikon: ID:n11053482-1
Further company coverage: 688180.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab